Positions

Selected Publications

Academic Article

Year Title Altmetric
2020 Less Toxic Chemotherapy in Locally Advanced Breast CancerSouthern Medical Journal.  113:559-563. 2020
2018 Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008Breast Cancer Research and Treatment.  167:107-116. 2018
2015 TBCRC 008: Early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancerJournal of Nuclear Medicine.  56:31-37. 2015
2014 How do i recommend extended adjuvant hormonal therapy?Current Treatment Options in Oncology.  15:55-62. 2014
2014 TBCRC 018: Phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastasesBreast Cancer Research and Treatment.  146:557-566. 2014
2012 Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: Results from the I-SPY 1 TRIAL - CALGB 150007/150012, ACRIN 6657Journal of Clinical Oncology.  30:3242-3249. 2012
2012 Chemotherapy response and recurrence-free survival in Neoadjuvant breast cancer depends on biomarker profiles: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)Breast Cancer Research and Treatment.  132:1049-1062. 2012
2011 An update on the dosimetric analysis of concurrent radiation therapy and trastuzumab on early cardiac events.Journal of Clinical Oncology.  29:121. 2011
2011 Long-term follow-up of dose-dense neoadjuvant chemotherapy in patients with stage II/III breast cancer.Journal of Clinical Oncology.  29:e11048. 2011
2010 Pilot trial of preoperative (Neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor-or progesterone receptor-positive breast cancerClinical Breast Cancer.  10:275-280. 2010
2006 Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer.Journal of Clinical Oncology.  24:10622. 2006
1998 Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: Implication for 5-fluorouracil-based chemotherapyClinical Cancer Research.  4:325-329. 1998
1995 The use of anthracyclines in the adjuvant treatment of breast cancer.Cancer Treatment Reviews.  21:199-214. 1995
1992 Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: a South-Eastern Cancer Study Group (SEG) trialEuropean Journal of Cancer.  28:1833-1837. 1992
1991 Epithelioid hemangioendothelioma: Ct manifestations and possible linkage to vinyl chloride exposure 1991
1991 Severe 5‐fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndromeCancer.  68:499-501. 1991
1991 Weight gain with breast cancer adjuvant treatmentCancer.  67:1954-1959. 1991
1988 The pathogenesis and clinical significance of cytologically detectable oral Candida in acute leukemia.Cancer.  62:2042-2046. 1988
1988 Phase I-II study of cisplatin, VP-16, MGBG, mitomycin, and vinblastine with radiation therapy for non-small-cell lung cancer. 1988
1988 A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancerJournal of Clinical Oncology.  6:1397-1400. 1988
1988 Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicityJournal of Clinical Investigation.  81:47-51. 1988
1988 In ReplyJAMA Surgery.  123:914. 1988
1987 Does Radical Mastectomy Still Have a Place in the Treatment of Primary Operable Breast Cancer?JAMA Surgery.  122:1317-1320. 1987
1986 Phase II trial of diaziquone in anthracycline-resistant adult soft tissue and bone sarcoma patients: A Southeastern Cancer Study Group trial 1986
1986 Megestrol acetate v tamoxifen in advanced breast cancer: Correlation of hormone receptors and responseSeminars in Oncology.  13:9-14. 1986
1986 Phase II evaluation of bolus gallium nitrate in lymphoproliferative disorders: A Southeastern Cancer Study Group trial 1986
1985 Intrarenal chloroma causing obstructive nephropathy: CT characteristics 1985
1985 Metastatic breast cancer: Preliminary results with oral hormonal therapySeminars in Oncology.  12:61-64. 1985
1984 Methods of nutritional support for hospitalized patientsAmerican Family Physician.  29:215-220. 1984
1984 Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a 'cycle active' non-cross-resistant combination in women with visceral metastatic breast cancer: A Southeastern Cancer Study Group projectJournal of Clinical Oncology.  2:643-651. 1984
1983 A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer - A Southeastern Cancer Study Group ProjectBreast Cancer Research and Treatment.  3:209-220. 1983
1983 A randomized prospective trial of radical (Halsted) mastectomy versus modified radical mastectomy in 311 breast cancer patientsAnnals of Surgery.  198:207-212. 1983
1983 Southeastern cancer study group: Breast cancer studies 1972-1982 1983
1981 The importance of leukopenia in breast cancer adjuvant therapy with melphalan (MPL) 1981
1979 Splenectomy for hematologic diseaseJournal of the American College of Surgeons.  149:509-512. 1979
1979 A consultant-extender system for breast cancer adjuvant chemotherapyACP journal club.  90:396-401. 1979
1978 Agranulocytosis Associated With Disopyramide TherapyJournal of the American Medical Association.  240:1857-1858. 1978
1977 A comparison of cyclophosphamide, adriamycin, 5‐fluorouracil (CAF) and cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A southeastern cancer study group projectCancer.  40:625-632. 1977
1974 Central nervous system complications after combination treatment with adriamycin (NSC 123127) and 5 (3,3 dimethyl 1 triazeno)imidazole 4 carboxamide (NSC 45388)Cancer chemotherapy reports. Part 1.  58:753-754. 1974

Chapter

Year Title Altmetric
2014 Systemic treatment of cancer with low and safe levels of radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies.  299-305. 2014

Education And Training

  • Doctor of Medicine, Tulane University 1968
  • Full Name

  • John Carpenter